Nexvel Biotech Accelerates Global Expansion at BEAUTYISTANBUL 2026
Advanced HA-Based Aesthetic Solutions Draw Attention from Global Buyers and Medical Professionals

South Korean medical aesthetic company Nexvel Biotech is accelerating its expansion into overseas markets after participating in BEAUTYISTANBUL 2026, one of the largest beauty exhibitions serving as a strategic hub connecting Europe, Asia, and the Middle East.

Recognized as a key international exhibition linking Europe, the Middle East, and CIS countries, BEAUTYISTANBUL brings together global beauty and aesthetic brands, medical professionals, distributors, and buyers. In recent years, the exhibition has also emerged as a major platform for competition in the medical aesthetics sector, particularly amid growing global demand for skin boosters and dermal fillers.

At this year’s exhibition, Nexvel Biotech showcased its core Aesthetic Medicines portfolio, including Dual HA Skin Booster, Aeshilo, CE-certified Roseeplla Filler, and the Amethea Skin Booster series. According to industry sources, the company attracted strong interest from overseas medical professionals and distributors, particularly regarding product stability, differentiated formulations, and clinical suitability.

Industry experts especially highlighted the company’s Dual HA-based skin booster technology. By combining high- and low-molecular-weight hyaluronic acid (HA), the formulation is designed to simultaneously enhance long-lasting hydration and skin elasticity. As the global medical aesthetics market increasingly shifts beyond simple volumizing procedures toward “skin quality” enhancement, this multifunctional approach is being viewed as a strong competitive advantage.

The CE-certified Roseeplla Filler also drew attention for its potential competitiveness in the European market. CE certification is recognized as a key indicator that a product meets the safety and quality standards required for entry into Europe, making it an essential factor in global market expansion. Industry officials noted that international markets are increasingly prioritizing product safety and clinical reliability over price competitiveness alone, emphasizing the growing importance of advanced technology and global certifications for Korean aesthetic manufacturers.

During the exhibition, Nexvel Biotech also engaged in active consultations with buyers from Europe, the Middle East, and Southeast Asia. Discussions regarding product supply partnerships and distribution agreements were particularly active in countries experiencing rapid growth in premium clinic-centered aesthetic markets, raising expectations for future expansion of the company’s global distributor network.

A representative from Nexvel Biotech stated, “Through our participation in BEAUTYISTANBUL 2026, we were able to effectively introduce our technological capabilities and product competitiveness to the global market. We will continue strengthening our presence in the international medical aesthetics industry through ongoing R&D investment and the expansion of global certifications.”

Meanwhile, the global medical aesthetics market continues to experience steady growth driven by rising demand for skin rejuvenation and anti-aging treatments. Skin boosters and dermal fillers are expected to remain among the key categories leading future market expansion, while industry attention is increasingly focused on how Korean companies’ technology-driven premium strategies will perform on the global stage.